Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999270 · ClinicalTrials.gov registry record · Phase 1
Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
A Phase 1 study of Glioma and Ganglioneuroma, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01999270: Completed Phase 1 study of Glioma and Ganglioneuroma, sponsored by Washington University School of Medicine.
NCT01999270 is a Phase 1 study of Glioma and Ganglioneuroma that has completed, run by Washington University School of Medicine. The registered enrollment target is 6 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01999270, a Phase 1 study of Glioma and Ganglioneuroma, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if FDOPA-PET/MRI imaging can predict response to treatment of bevacizumab.
Primary Outcome
The imaging is evaluated: (a) the uptake of PET tracer FDOPA measured by average and maximal standardized uptake values (SUVs) as well as tumor to normal brain ratios; and (b) tumor volumes defined by MRI signal abnormality.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Irinotecan
- DEVICE FDOPA-PET/MRI imaging
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT01999270 record still lists
NCT01999270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Glioma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01999270 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01999270 about?
NCT01999270 is a clinical study titled "Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors". To determine if FDOPA-PET/MRI imaging can predict response to treatment of bevacizumab.
What is the current status of trial NCT01999270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-04. Estimated completion is 2016-05.
What conditions does trial NCT01999270 study?
This clinical trial studies the following conditions: Glioma, Ganglioneuroma, Ganglioglioma, Astrocytoma, Oligoastrocytoma, Mixed, Glioblastoma Multiforme Glioma.
What interventions are being tested in trial NCT01999270?
The interventions under investigation include: Bevacizumab (DRUG), Irinotecan (DRUG), FDOPA-PET/MRI imaging (DEVICE).
Who is sponsoring clinical trial NCT01999270?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01999270 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01999270's enrollment target sits among peer trials
6 85th of 87 higher than 3 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia